Herbalife Nutrition Ltd vs Roivant Sciences Ltd. Common Shares — how do they compare? Herbalife Nutrition Ltd trades at $12.86 (market cap $1.34B), while Roivant Sciences Ltd. Common Shares trades at $35.16 (market cap $24.72B). The key difference: Roivant Sciences Ltd. Common Shares is far larger — about 18.4× Herbalife Nutrition Ltd's market cap, and Roivant Sciences Ltd. Common Shares is trading nearer its 52-week high, Herbalife Nutrition Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Herbalife Nutrition Ltd for 43 Days and Roivant Sciences Ltd. Common Shares for 0 Days on average.
| HLF | ROIV | |
|---|---|---|
Market Cap | $1.34B | $24.72B |
Volume | 1,589,457 | 6,279,442 |
Sector | Consumer Staples | Health |
52-Week High | $19.96 | $41.81 |
52-Week Low | $7.75 | $16.04 |
Typical Hold Time | 43 Days | 0 Days |
Enterprise Value | $3.18B | $20.99B |
Signals from Pluang's Aura AI — not financial advice
Herbalife (HLF) trades at $12.86, up 1.62% on the day, with a bullish technical signal and a consensus analyst price target of $19.00 implying significant upside. The company reported Q2 2026 EPS of $0.51, missing expectations, but reaffirmed full-year 2026 guidance. Financials show a net income margin of 3.16% for 2025, with a low P/E of 8.22 and P/S of 0.26, suggesting potential undervaluation. Recent news includes a $250 million share repurchase authorization and a planned CEO transition effective October 31, 2026.
The outlook for HLF is cautiously optimistic, with valuation metrics and analyst sentiment supporting a bullish case, but risks include recent earnings misses, high debt levels, and ongoing leadership changes. The stock presents a value opportunity if the company can execute on its growth and margin expansion plans while managing its leverage.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Herbalife Nutrition Ltd is an international nutrition company.
Read more on HLF →Roivant Sciences develops medicines by building and supporting biotechnology subsidiaries, known as Vants. Its programs span areas such as immunology, neuroscience, and rare diseases.
Read more on ROIV →